Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13507183 | 0.93 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL20170852 | 0.86 | OPRM1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL14263104 | 0.85 | OPRM1 (0.39) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL7987517 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL13977786 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL15214352 | 0.83 | OPRK1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL13013393 | 0.83 | OPRM1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL16747749 | 0.83 | OPRK1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL14996104 | 0.83 | OPRK1 (0.53) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL16509918 | 0.82 | OPRM1 (0.51) | OPRM1OPRD1OPRK1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | disclosed |
| EP-2137189-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | VTESSE LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | RAN, RANBP1, NCLN | OPRM1 60/4885OPRD1 406/4885OPRK1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.